304 related articles for article (PubMed ID: 30791097)
1. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
[TBL] [Abstract][Full Text] [Related]
2. Serum cell-free DNA levels are a useful marker for extramammary Paget disease.
Mijiddorj T; Kajihara I; Tasaki Y; Otsuka-Maeda S; Sakamoto R; Sawamura S; Kanazawa-Yamada S; Egashira S; Inoue K; Makino K; Miyashita A; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Jinnin M; Morinaga J; Ikeda T; Ihn H
Br J Dermatol; 2019 Sep; 181(3):505-511. PubMed ID: 30706452
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin 19 fragment 21-1 is a useful tumor marker for the assessment of extramammary Paget's disease.
Kato J; Sumikawa Y; Hida T; Kamiya T; Horimoto K; Kamiya S; Sato S; Takahashi H; Sawada M; Yamashita T
J Dermatol; 2017 Jun; 44(6):666-670. PubMed ID: 28150330
[TBL] [Abstract][Full Text] [Related]
4. Combined serum carcinoembryonic antigen and cytokeratin 19 fragment levels provide a sensitive biomarker for lymph node metastasis in extramammary Paget's disease.
Kato H; Nakamura M; Watanabe S; Oda T; Morita A
J Dermatol; 2020 Jul; 47(7):763-769. PubMed ID: 32415799
[TBL] [Abstract][Full Text] [Related]
5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
6. Monitoring serum cytokeratin 19 fragment 21-1 to determine the efficacy of docetaxel chemotherapy in advanced extramammary Paget's disease.
Onishi M; Maeda F; Akasaka T; Amano H
J Dermatol; 2019 Mar; 46(3):e83-e84. PubMed ID: 30194782
[No Abstract] [Full Text] [Related]
7. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors of Extramammary Paget's Disease.
Hatta N
Curr Treat Options Oncol; 2018 Aug; 19(10):47. PubMed ID: 30112691
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
12. Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget's Disease.
Urano-Takaoka M; Sumida H; Miyagawa T; Awaji K; Nagai K; Omatsu J; Miyake T; Sato S
Acta Derm Venereol; 2022 Jan; 102():adv00636. PubMed ID: 34904690
[TBL] [Abstract][Full Text] [Related]
13. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
14. Primary invasive extramammary Paget disease on penoscrotum: a clinicopathological analysis of 41 cases.
Shu B; Shen XX; Chen P; Fang XZ; Guo YL; Kong YY
Hum Pathol; 2016 Jan; 47(1):70-7. PubMed ID: 26508372
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease.
Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Mao HR
Br J Dermatol; 2009 Sep; 161(3):577-82. PubMed ID: 19438449
[TBL] [Abstract][Full Text] [Related]
17. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
Kibbi N; Owen JL; Worley B; Wang JX; Harikumar V; Downing MB; Aasi SZ; Aung PP; Barker CA; Bolotin D; Bordeaux JS; Cartee TV; Chandra S; Cho NL; Choi JN; Chung KY; Cliby WA; Dorigo O; Eisen DB; Fujisawa Y; Golda N; Halfdanarson TR; Iavazzo C; Jiang SIB; Kanitakis J; Khan A; Kim JYS; Kuzel TM; Lawrence N; Leitao MM; MacLean AB; Maher IA; Mittal BB; Nehal KS; Ozog DM; Pettaway CA; Ross JS; Rossi AM; Servaes S; Solomon MJ; Thomas VD; Tolia M; Voelzke BB; Waldman A; Wong MK; Zhou Y; Arai N; Brackett A; Ibrahim SA; Kang BY; Poon E; Alam M
JAMA Oncol; 2022 Apr; 8(4):618-628. PubMed ID: 35050310
[TBL] [Abstract][Full Text] [Related]
18. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
Gwak HK; Lee JH; Park SG
Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma.
Washino S; Hirai M; Matsuzaki A; Kobayashi Y
Urol Int; 2011; 87(4):420-8. PubMed ID: 22041857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
